Anti-Amyloid Therapies for Alzheimer's Disease and Amyloid-Related Imaging Abnormalities: Implications for the Emergency Medicine Clinician.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review without systematic review methodology or new human data
PubMed 39818674 · doi:10.1016/j.annemergmed.2024.12.002
What was done
The authors reviewed the clinical pharmacology, adverse effect profiles, and emergency department implications of recently approved anti-amyloid therapies for Alzheimer's disease, focusing on the detection and management of amyloid-related imaging abnormalities (ARIA).
What was found
The abstract reports no numerical outcome data or pooled statistics. It describes anti-amyloid therapies as infusions administered every 2 to 5 weeks that can cause ARIA-E (vasogenic edema) and ARIA-H (microhemorrhages and hemosiderin deposits). Because computed tomography lacks sensitivity to detect these microvascular changes, magnetic resonance imaging is required for diagnosis. Patients presenting with ARIA often display nonspecific symptoms including headache, lethargy, confusion, and seizures. The authors note these agents may increase the risk of hemorrhagic conversion if ischemic stroke patients receive thrombolytics and complicate decisions regarding anticoagulation.
Why it matters
As disease-modifying Alzheimer's drugs enter clinical practice, emergency physicians must recognize ARIA-related symptoms and understand imaging limitations to avoid misdiagnosis and safely manage acute stroke interventions.
Limits
This is a narrative overview rather than a systematic review or primary clinical study, and the abstract provides no quantitative incidence rates, risk ratios, or standardized protocols. Real-world emergency management data remain limited.
Cited by
- supports Alzheimer's disease accounts for approximately 70% of all dementia cases.